GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
The Alzheimer’s Revolution: Simple Blood Tests Spotting Risk Years Before Symptoms
For decades, Alzheimer’s disease has been a silent and elusive adversary. It crawls slowly through the brain, dismantling neural connections and building up toxic protein barriers long before the first lapse in memory occurs. Traditionally, confirming a diagnosis of Alzheimer’s has been a reactive process. Patients and their families had to wait for undeniable symptoms—confusion, forgetfulness, and changes in behavior—before seeking medical confirmation. By the time these symptoms manifest, significant and often irreversible brain damage has already occurred.
"Lonely Waves" and Genetic Timers: The Latest Alzheimer’s Breakthroughs Decoded
If you opened Google Scholar or picked up the latest issues of Nature Neuroscience or The Lancet Neurology over the past few days, you would spot two huge themes: how our sleep architecture betrays early brain changes, and how combining blood tests with genetics creates an exact clock for when symptoms will start.
Inside the Brain's Folding Architecture: How 3D Genome Structure Holds the Key to Alzheimer's
Learn how 3D genome folding in neurons impacts Alzheimer's disease. Discover the University of Pittsburgh's breakthrough research on chromatin remodelers and brain cell architecture.
Combating Alzheimer's: Current Treatments and Promising Pipeline Drugs
Alzheimer's disease is a devastating neurodegenerative disorder that affects millions worldwide. As the global population ages, the prevalence of Alzheimer's and related dementias is expected to rise significantly.
A Son's Reflections on Caring for His Dying Mother by Corey Hubbard
When I first became a caregiver for my terminally ill mother, I was thrust into a world I was wholly unprepared for. The woman who had always been my pillar of strength, my source of unwavering support, was now vulnerable and dependent on me.
Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research
Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.
The Regulatory Shift: Why Diversity Is Now a Technical Requirement
Discover how Glassbury AI’s agentic NLP platform, SYCQ 1.0, solves the FDA Diversity Action Plan (DAP) mandate and accelerates Phase III Alzheimer’s clinical trial matching.